Form 4: Mirum CFO Sells Shares, Exercises Options

Mirum Pharmaceuticals' CFO, Eric Bjerkholt, reported the sale of 8,000 common shares and the exercise of 2,954 employee stock options.

Summary

• Chief Financial Officer Eric Bjerkholt sold 8,000 shares of Mirum Pharmaceuticals common stock on August 11, 2025.
• The shares were sold at a weighted average price of $65.50, with individual sale prices ranging from $65.31 to $66.00.
• On August 12, 2025, Mr. Bjerkholt exercised employee stock options to acquire 2,954 shares of common stock at an exercise price of $26.49 per share.
• Following these transactions, Mr. Bjerkholt directly beneficially owns 31,190 shares of common stock.
• He also holds 29,046 unexercised employee stock options.
• The exercised options' vesting schedule included 1/4th vesting one year after January 23, 2024, with the balance vesting in 36 successive equal monthly installments from the first anniversary of the Vesting Commencement Date.
• An additional 290 shares of Common Stock were acquired by Mr. Bjerkholt on May 10, 2025, pursuant to the company's Employee Stock Purchase Plan.

Sentiment

Score: 4

Explanation: The sale of shares by a key executive could be viewed negatively, but the simultaneous exercise of options at a lower price indicates continued belief in the company's long-term value, creating a mixed signal.

Positives

• The exercise of employee stock options by the CFO indicates a continued commitment to the company and a belief in its long-term value, as shares are being acquired.
• The significant difference between the option exercise price ($26.49) and the sale price ($65.50) highlights a profitable transaction for the insider, reflecting potential value creation.

Negatives

• The sale of 8,000 shares by a key executive like the Chief Financial Officer could be perceived negatively by investors, potentially signaling a need for liquidity or a less optimistic outlook.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The filing details transactions by Eric Bjerkholt, the Chief Financial Officer, involving the sale of common stock and the exercise of employee stock options, which are considered related party dealings.

Stakeholder Impact

• Shareholders: The insider transactions provide transparency on executive holdings and can influence investor sentiment, with the sale potentially viewed negatively and the option exercise positively.
• Employees: The mention of shares acquired through the Employee Stock Purchase Plan indicates a benefit program available to employees.

Key Dates

Recommendation

The filing presents mixed signals for investors. While the Chief Financial Officer's sale of 8,000 shares could be interpreted as a negative signal regarding future prospects or a need for personal liquidity, the simultaneous exercise of 2,954 employee stock options at a significantly lower price ($26.49 vs. sale price of $65.50) demonstrates continued belief in the company's long-term value and profitability for the insider. Given these offsetting actions, a 'hold' recommendation is appropriate as the net impact on investor sentiment and company fundamentals is not definitively positive or negative based solely on this filing.

Keywords

Mirum Pharmaceuticals, MIRM, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Executive Compensation, CFO